stoxline Quote Chart Rank Option Currency Glossary
  
Azitra, Inc. (AZTR)
0.1781  -0.002 (-1.11%)    09-11 16:00
Open: 0.1821
High: 0.1853
Volume: 287,851
  
Pre. Close: 0.1801
Low: 0.1776
Market Cap: 2(M)
Technical analysis
2026-09-11 4:42:39 PM
Short term     
Mid term     
Targets 6-month :  0.22 1-year :  0.25
Resists First :  0.18 Second :  0.22
Pivot price 0.17
Supports First :  0.14 Second :  0.12
MAs MA(5) :  0.17 MA(20) :  0.16
MA(100) :  0.17 MA(250) :  0.29
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  83.8 D(3) :  82
RSI RSI(14): 61.7
52-week High :  1.09 Low :  0.1
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ AZTR ] has closed below upper band by 38.6%. Bollinger Bands are 5.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.19 - 0.19 0.19 - 0.19
Low: 0.17 - 0.18 0.18 - 0.18
Close: 0.18 - 0.18 0.18 - 0.18
Company Description

Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.

Headline News

Wed, 09 Sep 2026
Why Is AZTR Stock Rising Today? - Stocktwits

Tue, 08 Sep 2026
Initial data on a program targeting fine lines and wrinkles will be shared by Azitra - Stock Titan

Sat, 22 Aug 2026
Azitra Regains NYSE American Listing Compliance Status - The Globe and Mail

Fri, 21 Aug 2026
Azitra (NYSE: AZTR) wins back listing under new NYSE watch period - Stock Titan

Fri, 21 Aug 2026
Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards - Yahoo Finance

Wed, 12 Aug 2026
Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
AMEX
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 0 (M)
Held by Insiders 0 (%)
Held by Institutions 0 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) 0 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android